"Designing Growth Strategies is in our DNA"

U.S. Immunoglobulin Market Size, Share & COVID-19 Impact Analysis, By Route of Administration (Intravenous, and Subcutaneous), By Indication (Primary Immunodeficiency, Secondary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Syndrome, Immune Thrombocytopenic Purpura, Multifocal Motor Neuropathy, and Others), By Form (Liquid and Lyophilized), By End-user (Hospitals, Clinics, and Homecare), and Country Forecast, 2023-2030

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI108226

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Pipeline Analysis, by Key Players
    2. Key Industry Developments: Mergers, Acquisitions, Partnerships, etc.
    3. Overview of Regulatory Scenario in the U.S.
    4. Prevalence of Primary Immunodeficiency (PID), in the U.S., 2022
    5. Impact of COVID-19 on the U.S. Immunoglobulin Market
  5. U.S. Immunoglobulin Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous (IV)
      2. Subcutaneous (SC)
    2. Market Analysis, Insights and Forecast – By Indication
      1. Primary Immunodeficiency (PI)
      2. Secondary Immunodeficiency (SID)
      3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      4. Guillain-Barré Syndrome
      5. Immune Thrombocytopenic Purpura (ITP)
      6. Multifocal Motor Neuropathy (MMN)
      7. Others
    3. Market Analysis, Insights and Forecast – By Form
      1. Liquid
      2. Lyophilized
    4. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Clinics
      3. Homecare
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. Shire
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      2. CSL Behring
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      3. Grifols, S.A.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      4. Kedrion S.p.A
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      5. Octapharma
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      6. Bio Products Laboratory Ltd.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      7. Biotest AG
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      8. China Biologic Products Holdings, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      9. LFB Group
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      10. Shanghai RAAS Blood Products Co., Ltd.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Pipeline Analysis, by Key Players
    2. Key Industry Developments: Mergers, Acquisitions, Partnerships, etc.
    3. Overview of Regulatory Scenario in the U.S.
    4. Prevalence of Primary Immunodeficiency (PID), in the U.S., 2022
    5. Impact of COVID-19 on the U.S. Immunoglobulin Market
  5. U.S. Immunoglobulin Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous (IV)
      2. Subcutaneous (SC)
    2. Market Analysis, Insights and Forecast – By Indication
      1. Primary Immunodeficiency (PI)
      2. Secondary Immunodeficiency (SID)
      3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      4. Guillain-Barré Syndrome
      5. Immune Thrombocytopenic Purpura (ITP)
      6. Multifocal Motor Neuropathy (MMN)
      7. Others
    3. Market Analysis, Insights and Forecast – By Form
      1. Liquid
      2. Lyophilized
    4. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Clinics
      3. Homecare
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. Shire
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      2. CSL Behring
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      3. Grifols, S.A.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      4. Kedrion S.p.A
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      5. Octapharma
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      6. Bio Products Laboratory Ltd.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      7. Biotest AG
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      8. China Biologic Products Holdings, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      9. LFB Group
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      10. Shanghai RAAS Blood Products Co., Ltd.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
Read Less

Figure 1: U.S. Immunoglobulin Market Revenue Breakdown (USD billion, %) by Indication, 2022 & 2030

Figure 2: U.S. Immunoglobulin Market Value Share (%), by Indication, 2022 & 2030

Figure 3: U.S. Immunoglobulin Market Value Share (%), by Route of Administration, 2022 & 2030

Figure 4: U.S. Immunoglobulin Market Value Share (%), by Form, 2022 & 2030

Figure 5: U.S. Immunoglobulin Market Value Share (%), by End-user, 2022 & 2030

Figure 6: U.S. Immunoglobulin Market Share (%), By Company, 2022

Table 1: U.S. Immunoglobulin Market Revenue (USD billion) Forecast, by Indication, 2019–2030

Table 2: U.S. Immunoglobulin Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2030

Table 3: U.S. Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2019–2030

Table 4: U.S. Immunoglobulin Market Revenue (USD billion) Forecast, by End-user, 2019–2030

U.S. Immunoglobulin Market
  • 2019-2030
  • 2022
  • 2019-2021
  • 80
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports